遗传性乳腺癌外科治疗

外科理论与实践››2022,Vol. 27››Issue (05): 392-395.doi:10.16139/j.1007-9610.2022.05.003

陈益定(), 吴世杰

浙江大学医学院附属第二医院乳腺外科，浙江杭州 310009

收稿日期:2022-08-01出版日期:2022-09-25发布日期:2022-11-10
通讯作者:陈益定 E-mail:ydchen@zju.edu.cn
基金资助:
国家自然科学基金(82072900)

Surgical treatment of hereditary breast cancer

CHEN Yiding(), WU Shijie

Received:2022-08-01Online:2022-09-25Published:2022-11-10
Contact:CHEN Yiding E-mail:ydchen@zju.edu.cn

摘要/Abstract

中图分类号:

R737.9

陈益定, 吴世杰. 遗传性乳腺癌外科治疗[J]. 外科理论与实践, 2022, 27(05): 392-395.

CHEN Yiding, WU Shijie. Surgical treatment of hereditary breast cancer[J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 392-395.

参考文献27

[1]	Chen W, Zheng R, Baade P, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[3]	Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer[J]. N Engl J Med, 2021, 384(5):440-451.
[4]	Breast Cancer Association Consortium, Dorling L, Carvalho S, et al. Breast cancer risk genes - association analysis in more than 113,000 women[J]. N Engl J Med, 2021, 384(5):428-439.
[5]	Kurian AW, Ward KC, Abrahamse P, et al. Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019[J]. J Clin Oncol, 2021, 39(15):1631-1640.
[6]	Sun J, Meng H, Yao L, et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients[J]. Clin Cancer Res, 2017, 23(20):6113-6119.
[7]	Deng M, Chen HH, Zhu X, et al. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China[J]. Int J Cancer, 2019, 145(6):1517-1528.
[8]	Liu Y, Wang H, Wang X, et al. Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort[J]. J Hematol Oncol, 2021, 14(1):18.
[9]	Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23):2402-2416.
[10]	Ducy M, Sesma-Sanz L, Guitton-Sert L, et al. The tumor suppressor PALB2: inside out[J]. Trends Biochem Sci, 2019, 44(3):226-240.
[11]	Zhou J, Wang H, Fu F, et al. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing[J]. Cancer, 2020, 126(14):3202-3208.
[12]	Cybulski C, Kluzniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis[J]. Lancet Oncol, 2015, 16(6):638-644.
[13]	Yang X, Leslie G, Doroszuk A, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families[J]. J Clin Oncol, 2020, 38(7):674-685.
[14]	Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy[J]. Breast Cancer Res Treat, 2010, 121(2):389-398.
[15]	Nilsson MP, Hartman L, Kristoffersson U, et al. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer[J]. Breast Cancer Res Treat, 2014, 147(3):571-578.
[16]	Cao W, Xie Y, He Y, et al. Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer follow-ing breast-conserving surgery with BRCA1 and BRCA2 mutation in China[J]. Breast Cancer Res Treat, 2019, 175(3):749-754.
[17]	van den Broek AJ, Schmidt MK, van′t Veer LJ, et al. Prognostic impact of breast-conserving therapyversusmastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients[J]. Ann Surg, 2019, 270(2):364-372.
[18]	Wan Q, Su L, Ouyang T, et al. Comparison of survival after breast-conserving therapyvs.mastectomy among patients with or without the BRCA1/2 variant in a large series of unselected Chinese patients with breast cancer[J]. JAMA Netw Open, 2021, 4(4):e216259.
[19]	Manning AT, Wood C, Eaton A, et al. Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance[J]. Br J Surg, 2015, 102(11):1354-1359.
[20]	Yao K, Liederbach E, Tang R, et al. Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature[J]. Ann Surg Oncol, 2015, 22(2):370-376.
[21]	Kaas R, Verhoef S, Wesseling J, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer[J]. Ann Surg, 2010, 251(3):488-492.
[22]	Carbine NE, Lostumbo L, Wallace J, et al. Risk-reducing mastectomy for the prevention of primary breast cancer[J]. Cochrane Database Syst Rev, 2018, 4(4):CD002748.
[23]	Evron E, Ben-David AM, Goldberg H, et al. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer[J]. Ann Oncol, 2019, 30(3):412-417.
[24]	Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline[J]. J Clin Oncol, 2020, 38(18):2080-2106.
[25]	Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis[J]. Ann Oncol, 2013, 24(8):2029-2035.
[26]	O′Connell RL, Tasoulis MK, Hristova E, et al. Satisfaction with long-term aesthetic and 10 years oncologic outcome following risk-reducing mastectomy and implant-based breast reconstruction with or without nipple preservation[J]. Cancers (Basel), 2022, 14(15):3607.
[27]	中国抗癌协会家族遗传性肿瘤专业委员会. 中国家族遗传性肿瘤临床诊疗专家共识(2021年版)(1)—家族遗传性乳腺癌[J]. 中国肿瘤临床, 2021, 48(23):1189-1195.

遗传性乳腺癌外科治疗

Surgical treatment of hereditary breast cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献27

相关文章15

编辑推荐

Metrics

本文评价

[1]	朱正纲.胃癌外科综合治疗的若干进展与展望[J]. 外科理论与实践, 2023, 28(01): 1-6.
[2]	张吉祥, 谢智华, 综述, 李炜, 姜小清, 审校.肝内胆管癌的分型和外科治疗热点[J]. 外科理论与实践, 2022, 27(05): 478-482.
[3]	陈承坤综述, 郭伯敏, 邓先兆, 伍波, 樊友本审校.甲状腺髓样癌的诊治现状[J]. 外科理论与实践, 2022, 27(03): 276-280.
[4]	黄纪伟, 邱国腾, 曾勇.肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118.
[5]	包全, 邢宝才.复杂双叶多发性结肠直肠癌肝转移外科治疗策略[J]. 外科理论与实践, 2022, 27(02): 128-130.
[6]	杨建军, 宋致成, 顾岩.肥胖合并食管裂孔疝的外科治疗策略[J]. 外科理论与实践, 2021, 26(05): 394-398.
[7]	王冲, 程石.肝内胆管癌——国内外专家共识及指南解读[J]. 外科理论与实践, 2021, 26(02): 124-129.
[8]	余莉,.脓胸的治疗原则及进展[J]. 内科理论与实践, 2020, 15(01): 21-24.
[9]	汤永喆, 王杰, 何奇.妊娠期乳腺癌诊治策略[J]. 外科理论与实践, 2019, 24(05): 400-405.
[10]	沈宇辉.规范癌症骨转移的外科治疗[J]. 外科理论与实践, 2019, 24(05): 417-420.
[11]	李恒宇, 盛湲.遗传性乳腺癌基因检测的10个热点[J]. 外科理论与实践, 2019, 24(05): 406-411.
[12]	吴峻立, 苗毅.慢性胰腺炎的外科诊治现状[J]. 外科理论与实践, 2019, 24(03): 194-198.
[13]	兰平, 蔡泽荣.腹腔镜外科治疗在克罗恩病中的应用[J]. 外科理论与实践, 2018, 23(05): 402-404.
[14]	顾晋, 韩子翰.早期结肠直肠癌的治疗策略[J]. 外科理论与实践, 2018, 23(05): 390-393.
[15]	焦臣宇, 张慧, 王科, 武正山, 吴晓峰, 韩晟, 王东, 季顾惟, 李相成,.肝内胆管癌手术切除预后的相关因素研究[J]. 外科理论与实践, 2017, 22(06): 509-514.